Fecal calprotectin test is a noninvasive diagnostic test used to determine inflammation in the digestive tract. It measures the levels of calprotectin protein in stool, which indicates the presence of neutrophils that have migrated from the bloodstream to the intestine due to inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. Fecal calprotectin test holds advantages like accuracy, noninvasiveness, safety, and high sensitivity and specificity for detection of intestinal inflammation. With rising cases of IBD globally, fecal calprotectin testing acts as an important tool for diagnosis and management of IBD. The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Increasing incidences of inflammatory bowel diseases globally is estimated to propel the growth of fecal calprotectin test market. According to Crohn's & Colitis Foundation, an estimated 3.1 million Americans suffer from IBD, with 71,000 new cases diagnosed each year. Similarly, European Crohn's and Colitis Organisation states IBD affects an estimated 2.5–3 million people in Europe. With rising prevalence of IBD worldwide due to changes in lifestyle and environmental factors, demand for reliable diagnostic tests like fecal calprotectin test is expected to surge in the coming years. This presents a major market opportunity for manufacturers to increase penetration in IBD diagnosis through promotional activities and partnerships with healthcare providers.

Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate as the capital required to establish full clinical laboratories and research facilities is substantial. Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of substitute products. However, the importance of early diagnosis enhances buyer dependence on the product. Bargaining power of suppliers: The bargaining power of suppliers is moderate as the key raw materials required are available from multiple sources globally. Threat of new substitutes: The threat of new substitutes is low as there are limited alternatives available for non-invasive fecal calprotectin testing. Competitive rivalry: The competitive rivalry in the market is high due to the presence of numerous global as well as regional players.

SWOT Analysis

Strengths: Growing prevalence of inflammatory bowel diseases globally and widespread acceptance of fecal calprotectin testing. Weaknesses: Requirement of specialized infrastructure for sample collection and analysis. High capital investment needs to establish clinical laboratories. Opportunities: Emerging economies provide large untapped markets. Development of rapid point-of-care fecal calprotectin tests. Threats: Stringent regulatory environment. Reimbursement issues pose challenges in market adoption.

Key Takeaways

The global Fecal Calprotectin Test Market is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2023 is estimated to be US$ 140.6 Mn. Asia Pacific region currently dominates the market and is projected to exhibit the highest CAGR during the forecast period. This can be attributed to rising environmental pollution levels and increasing prevalence of inflammatory bowel diseases in highly populated countries like India and China.

Regional analysis of the Asia Pacific market comprises over 40% value share and is driven by factors such as growing health awareness, increasing healthcare expenditure, rapidly developing healthcare infrastructure and large patient pool.

Key players operating in the Fecal Calprotectin Test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc. Thermo Fisher Scientific Inc. is a leading player with wide product offerings in both ELISA and point-of-care formats.

Get more insights on this topic: https://www.trendingwebwire.com/fecal-calprotectin-test-market-analysis-scope/